Back to Search
Start Over
Perspectives for cancer therapies with cdk2 inhibitors
- Source :
- Drug Resistance Updates. 4:347-367
- Publication Year :
- 2001
- Publisher :
- Elsevier BV, 2001.
-
Abstract
- Modern anticancer strategies are designed against specific molecular targets with the goal of sparing normal, non-neoplastic tissues. Choosing specific molecular targets, however, is problematic. Cdk2 (Cyclin dependent kinase 2, cell division kinase 2, p33) is an important candidate target for therapeutic intervention. Phosphorylation of retinoblastoma protein (pRb) by Cdk2 is the penultimate step in the transition from G1 to S phase. Inhibition of this step could potentially result in inhibition of proliferation, cytostasis and possibly apoptosis in human tumors. Cdk2 also plays a critical role in the transition through S phase and the S to G2 transition as well. Inhibitors of the cyclin dependent kinases, such as flavopiridol and UCN-01, are currently in clinical trials. While demonstrating clinical activity, neither acts specifically against Cdk2. Other more specific Cdk2 inhibitors are currently in preclinical development. Further studies to explore the therapeutic worth of such agents are warranted.
- Subjects :
- Cyclin-Dependent Kinase Inhibitor p21
DNA Replication
Cancer Research
Antineoplastic Agents
Apoptosis
Cell Cycle Proteins
Protein Serine-Threonine Kinases
Retinoblastoma Protein
S Phase
Cyclin-dependent kinase
Cyclins
CDC2-CDC28 Kinases
medicine
Humans
Pharmacology (medical)
Phosphorylation
Cyclin-Dependent Kinase Inhibitor p16
Pharmacology
Estradiol
biology
Kinase
Cyclin-dependent kinase 4
Cyclin-Dependent Kinase 2
Cyclin-dependent kinase 2
G1 Phase
Retinoblastoma protein
Cancer
medicine.disease
Cytostasis
Cyclin-Dependent Kinases
E2F Transcription Factors
Cell biology
DNA-Binding Proteins
Infectious Diseases
Oncology
biology.protein
Cancer research
Cyclin-Dependent Kinase-Activating Kinase
Transcription Factors
Subjects
Details
- ISSN :
- 13687646
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- Drug Resistance Updates
- Accession number :
- edsair.doi.dedup.....cb4ee50021aeb8126a635147ff907336